Researchers at the University of South Florida have developed therapeutic compositions of myricanol derivatives for the treatment of neurodegenerative diseases associated with the abnormal accumulation of protein tau.
The intracellular aggregation of abnormal protein tau is a major pathologic feature of many neurodegenerative diseases collectively referred to as tauopathies. Tau normally functions to stabilize microtubules in neurons. However, its unwanted aggregation is characteristic of more than 15 neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. Presently, the development of tauopathy therapeutics focus primarily on agents that prevent the aggregation of tau proteins. However, new research shows that agents that degrade or destabilize tau intermediates, clear abnormal tau from cells, or otherwise reduce intracellular tau levels may be a more promising therapeutic approach.
Brochure
